Lantheus Medical Imaging, Inc. - Strategic SWOT Analysis Review
provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
Lantheus Medical Imaging, Inc. (Lantheus Medical), formerly Bristol-Myers Squibb Medical Imaging, Inc., is a pharmaceutical company. It carries out research, development and marketing of medical imaging products for nuclear and ultrasound cardiovascular diagnostic imaging procedures. The company offers ABLAVAR, Cardiolite, TechneLite and DEFINITY. The company's DEFINITY is a cardiac ultrasound contrast agent. Its Cardiolite is a cardiac perfusion imaging agent. The company's products are sold under the brand names DEFINITY, Cardiolite, TechneLite, ABLAVAR, INTELLPIN and NEUROLITE.
Lantheus Medical Imaging, Inc. Key Recent Developments
Mar 14, 2014 A.G. Schneiderman Announces $6.2 Million Settlementwith Lantheus Medical Imaging & Bristol-Myers Squibb For Failing To Pay New York Corporate Income Taxes
Nov 06, 2013 Lantheus Medical Imaging to Host Third Quarter 2013 Conference Call on November 13, 2013 at 3:00 p.m. Eastern Time
Oct 29, 2013 Lantheus Releases Preliminary Results from Phase 3 Clinical Trial of Flurpiridaz F 18 for the Detection of Coronary Artery Disease
Sep 10, 2013 Lantheus Medical Imaging to Present at Imperial Capital Global Opportunities Conference on September 19, 2013
Aug 01, 2013 Lantheus Medical Imaging to Host Second Quarter 2013 Conference Call on August 8, 2013 at 4:00 p.m. Eastern TimeReasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
: Some sections may be missing if data is unavailable for the company.